Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

This study has been completed.
Information provided by (Responsible Party):
OPKO Health, Inc. ( OPKO IP Holdings II, Inc. ) Identifier:
First received: April 23, 2009
Last updated: September 29, 2014
Last verified: February 2010
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2009
  Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)